Trends in radiotherapy inpatient admissions in Germany: a population-based study over a 10-year period

Daniel Medenwald1 · Rainer Fietkau2 · Gunther Klautke3 · Susan Langer1 · Florian Würschmidt4 · Dirk Vordermark1

Received: 21 January 2021 / Accepted: 16 July 2021 / Published online: 3 September 2021
© The Author(s) 2021

Abstract
Objective With the increasing complexity of oncological therapy, the number of inpatient admissions to radiotherapy and non-radiotherapy departments might have changed. In this study, we aim to quantify the number of inpatient cases and the number of radiotherapy fractions delivered under inpatient conditions in radiotherapy and non-radiotherapy departments.

Methods The analysis is founded on data of all hospitalized cases in Germany based on Diagnosis-Related Group Statistics (G-DRG Statistics, delivered by the Research Data Centers of the Federal Statistical Office). The dataset includes information on the main diagnosis of cases (rather than patients) and the performed procedures during hospitalization based on claims of reimbursement. We used linear regression models to analyze temporal trends. The considered data encompass the period from 2008 to 2017.

Results Overall, the number of patients treated with radiotherapy as inpatients remained constant between 2008 (N = 90,952) and 2017 (N = 88,998). Starting in January 2008, 48.9% of 4000 monthly cases received their treatment solely in a radiation oncology department. This figure decreased to 43.7% of 2971 monthly cases in October 2017. We found a stepwise decrease between December 2011 and January 2012 amounting to 4.3%. Fractions received in radiotherapy departments decreased slightly by 29.3 (95% CI: 14.0–44.5) fractions per month. The number of days hospitalized in radiotherapy departments decreased by 83.4 (95% CI: 59.7,107.0) days per month, starting from a total of 64,842 days in January 2008 to 41,254 days in 2017. Days per case decreased from 16.2 in January 2008 to 13.9 days in October 2017.

Conclusion Our data give evidence to the notion that radiotherapy remains a discipline with an important inpatient component. Respecting reimbursement measures and despite older patients with more comorbidities, radiotherapy institutions could sustain a constant number of cases with limited temporal shifts.

Keywords Inpatient cases · Radiotherapy departments · DRG data · Germany · Non-radiotherapy departments

Introduction
Cancer remains a major health care problem in Europe, with an estimated number of 3.2 million new cases and 1.7 million deaths per year in an ageing population [1, 2]. Radiotherapy is a cornerstone of modern cancer therapy, with half of all cancer patients in Europe receiving radiotherapy at least once [3]. The application of radiotherapy has different objectives, aimed at curative treatment, local control, or palliation [4]. It is one of the most cost-effective cancer treatments and used differently in the different European countries [5]. Germany has the highest number of radiotherapy centers (n = 289) in Europe, followed by France (n = 177) and Italy (n = 172) [3, 6]. Borras et al. calculated that the demand for radiation treatment in Europe...
will probably increase by about 16% between 2012 and 2025 [7].

In Germany, patients receive inpatient radiotherapy either in radiation oncology departments or in departments with a different specialty where radiotherapy institutions serve as a provider of treatment. This two-arm concept entails important consequences for the field of radiotherapy and health services in oncology.

Various developments in the treatment of cancer patients have taken place in recent years. One trend is the introduction of new treatment options, including new cancer drugs [2].

While most of the treatment in radiotherapy takes place in an outpatient setting, inpatient treatment is a cornerstone when it comes to radiochemotherapy or care of patients in poor health. With more advanced treatments such as immunotherapy that have become essential for the treatment of multiple solid malignancies during recent years, the number of administered cancer drugs has increased and indications have widened [2]. As a result, multimodal concepts have developed [2] and treatment options for older patients have increased considerably, such as in the case of non-small cell lung cancer [7, 8].

A further development is concomitant radiochemotherapy, which, compared to sequential radiochemotherapy, improves overall survival in patients with locally advanced non-small-cell lung cancer (NSCLC) [8] but also in other cancers such as those of the head and neck. Bonner et al. showed that cetuximab in addition to radiotherapy is superior to radiotherapy alone for locally advanced head and neck cancer [9]. Cetuximab was also advantageous when added to concurrent chemotherapy [10], but showed no benefit when it was compared to cisplatin as a single agent [11, 12].

These developments could give rise to a trend where other medical specialties supplement inpatient treatment in radiotherapy departments. Alternatively, an increased demand for inpatient treatment with concomitant radiochemotherapy might lead to increasing case numbers in radiotherapy.

Thus, radiotherapy inpatient departments might lose or gain importance, transforming the field of radiation oncology to a mainly outpatient setting. In this study, we aim to assess and quantify the proportion of inpatients receiving radiotherapy in a genuine radiation oncology department and possible developments since 2008.

**Methods**

Our analysis is based on data of all hospitalized cases in Germany as recorded in the Diagnosis-Related Group Statistics (G-DRG Statistics: German version for inpatients) delivered by the Research Data Centers (RDC) of the Federal Statistical Office and the statistical offices of the federal states [13]. Inpatient health care providers use the G-DRG coding to charge their services and to claim reimbursements. The dataset includes information on the main diagnosis and the procedures performed during the hospitalization. Due to data privacy, the data are based on cases rather than individual patients [4]; that is, the identity of the patient is not coded, only the treated case can be identified. The considered data encompass the period from 2008 (IMRT recorded for the first time) to 2017, and we report them in a monthly pattern (smallest available time unit). We excluded November and December 2017 from the analyses as hospitalizations might well have exceeded the recording period of 2017. As mentioned, the RDC provides the data for public use. Thus, no approval by an ethics committee was required to conduct the analyses (terms outlined by the RDC apply).

Radiotherapeutic procedures were identified by means of the *Operationen- und Prozedurenschlüssel* (OPS). Cases with an OPS code of 8-522.x (high-voltage radiotherapy, subsequently referred to as “total cases”) were considered for subsequent analyses. Apart from the number of cases, we also report the number of fractions delivered (each coded as a separate procedure in the DRG statistic). The variable “month” as presented here refers to the month of admission. In total, 0.8 million cases entered subsequent analyses.

We defined treatment by means of radiation as encoded by the OPS codes 8-542 (chemotherapy with minor complexity) and 8-543 (chemotherapy with medium complexity). In the subsequent text, “radiochemotherapy” refers to radiation and chemotherapy given during one hospital stay.

In a sensitivity analysis, we included all radiotherapy procedures with an OPS code of 8-520, 8-521 (orthovoltage therapy), 8-522, 8-523 (other forms of high-voltage radiotherapy including stereotactic body radiotherapy, total body irradiation), 8-524 (brachytherapy), and 8-525 (other forms of brachytherapy including interstitial brachytherapy).

Departments were defined in accordance with the definition of the Federal Statistical Office as structural units within a hospital. Main and sub-departments were regarded as separate entities (e.g., radiotherapy ward/department as part of the oncology department was regarded as separate) [13].

We additionally computed the Charlson Comorbidity Index (CCI) in order to assess the clinical performance status of hospitalized cases.

**Statistics**

We used linear regression models to analyze temporal trends, with “month” as the independent variable. In
the models reporting hospitalization time, we computed a smoothed trend with respective confidence intervals using the “SSModel” function in R. In the results section we report 95% confidence intervals (CI). All statistical analyses were performed using SAS 9.3 and R (R version 3.6.0, R Core Team (2019). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/).

Results

Radiotherapy cases

Starting in January 2008, 4000 cases (number per month) received their treatment solely in a radiation oncology department, which decreased to 2971 cases in October 2017. In contrast, there were 4177 cases hospitalized in a non-radiotherapy department in January 2008, decreasing to 3825 at the end of the observational period (annual data in Table 1 and Fig. S7 of the supplement).

Table 1 Annual sums (cases and fractions) and the year-specific mean of inpatient days per case

| Year | Cases (n per year) | Fractions (n per year) | Days/case (mean) |
|------|--------------------|------------------------|------------------|
|      | RT | Both | Non-RT | Sum   | RT | Both | Non-RT | Sum   | RT | Non-RT |
| 2008 | 45,144 | 8872 | 36,936 | 90,952 | 377,963 | 123,286 | 267,639 | 768,888 | 14.1 | 19.9 |
| 2009 | 44,669 | 9020 | 37,197 | 90,886 | 371,493 | 125,475 | 264,826 | 761,794 | 14.1 | 20.2 |
| 2010 | 46,494 | 9117 | 40,008 | 95,619 | 369,585 | 128,430 | 286,187 | 784,202 | 14.0 | 19.6 |
| 2011 | 48,545 | 9247 | 40,240 | 98,382 | 370,287 | 130,778 | 291,574 | 792,639 | 13.7 | 19.5 |
| 2012 | 40,406 | 9503 | 39,485 | 89,394 | 360,399 | 132,996 | 282,609 | 776,004 | 14.9 | 19.3 |
| 2013 | 40,144 | 9532 | 39,808 | 89,484 | 322,768 | 122,405 | 256,981 | 702,154 | 14.7 | 19.0 |
| 2014 | 40,795 | 9918 | 40,929 | 91,642 | 356,164 | 140,173 | 292,133 | 788,470 | 14.2 | 18.8 |
| 2015 | 40,949 | 9257 | 39,285 | 89,491 | 355,807 | 127,604 | 279,456 | 762,867 | 13.7 | 18.7 |
| 2016 | 39,216 | 9626 | 40,156 | 88,998 | 346,900 | 132,475 | 288,180 | 767,555 | 14.0 | 18.5 |

Table 2 Results from linear regression analyses. Values report the absolute change per month or the change in percentage points per year over the observational period

|                      | Radiotherapy units | All units |
|----------------------|--------------------|----------|
|                      | Absolute           | Relative (%) | Absolute | Relative (%) | Proportion (percentage points) |
| Hospitalization time | –83.4, (–107, –59.7) | –0.15, (–0.2, –0.11) | –268, (–322.7, –213.3) | –0.22, (–0.26, –0.17) | – |
| Cases                | –6.3, (–7.8, –4.7)  | –0.16, (–0.2, –0.12) | –4.4, (–7.1, –1.6) | –0.06, (–0.09, –0.02) | –0.056, (–0.063, –0.048) |
| Fractions            | –29.3, (–44.5, –14) | –0.09, (–0.14, –0.04) | –15.6, (–46.2, 15.1) | –0.02, (–0.07, 0.02) | –0.034, (–0.041, –0.028) |
| Hospitalization time | –13.2, (–22.3, –4.1) | –0.08, (–0.13, –0.02) | –41.2, (–59.4, –23.1) | –0.11, (–0.16, –0.06) | – |
| Cases                | 0.9, (0.1, 1.6)     | 0.05, (0.01, 0.09)  | 1.5, (0.3, 2.8)    | 0.05, (0.01, 0.09)  | 0, (–0.008, 0.008)   |
| Fractions            | 3.4, (–3.4, 10.3)   | 0.03, (–0.03, 0.08) | 10.4, (–2.2, 23)   | 0.04, (–0.01, 0.1)  | –0.009, (–0.017, –0.001) |

We found a linear decrease in case numbers across the observational period in all cases with radiotherapy considering all departments. This was not true when radiochemotherapy was administered, where we found a trend for an increase in case numbers (0.8 cases per month, 95% CI: 0.1–1.6; Table 2). Consequently, the effect of a decrease was strongest when we considered cases without radiochemotherapy (Fig. S1). The relative decline was most pronounced in the subgroup of cases with radiochemotherapy treated in radiotherapy departments alone (–0.16% per month; 95% CI: –0.2, –0.12).

Modelling the proportion of cases treated in radiotherapy departments, we found a stepwise decrease between December 2011 and January 2012 amounting to 4.0% (3.3–4.7%; Fig. 1).

Fractions

Similarly, patients hospitalized solely in a radiation oncology department received 37,927 fractions in January 2008, decreasing to 26,310 fractions in October 2017. On average, the linear decrease was 29.3 (95% CI: 14.0–44.5; Fig. 2) fractions per month. Annual summary statistics are shown
Fig. 1  a Temporal course of cases with any form of radiotherapy treated in radiotherapy departments (red), non-radiotherapy departments (black), and other departments (blue). b Proportion of cases with any form of radiotherapy exclusively treated in radiotherapy departments. c Temporal course of cases with radiochemotherapy treated in radiotherapy departments (red), non-radiotherapy departments (black), and other departments (blue). d Proportion of cases with radiochemotherapy exclusively treated in radiotherapy departments.
Fig. 2  a Temporal course of fractions in cases with any form of radiotherapy treated in radiotherapy departments (red), non-radiotherapy departments (black), and other departments (blue). b Proportion of cases with any form of radiotherapy exclusively treated in radiotherapy departments. c Temporal course of fractions in cases with radiochemotherapy treated in radiotherapy departments (red), non-radiotherapy departments (black), and other departments (blue). d Proportion of cases with radiochemotherapy exclusively treated in radiotherapy departments.
in Table 1 and in Fig. S7 of the supplement. The only statistically significant decline was found in cases treated in radiotherapy departments considering all radiotherapies (−0.09%; 95% CI −0.14, −0.04; Table 2).

In addition, we observed an increase in fractions per case in radiotherapy departments (Fig. 3).

Days of hospitalization

Days hospitalized in radiotherapy departments decreased during the observational period by 83.4 days per month (95% CI: 59.7, 107.0; Fig. 4), starting from a total of 64,842 days in January 2008.

Analyzing the hospitalization time for patients receiving radiochemotherapy in radiotherapy departments, we found a decrease by 13.2 days (95% CI: 4.1, 22.3; Fig. 4) per month during the observational period. In the same line, there was a minor decrease by 41.2 days (95% CI: 23.1, 59.4) when all patients including those treated in a non-radiotherapy department were considered. There was a steep rise in the monthly average of inpatient days per case in a radiotherapy department in January 2012 (Fig. S2).

In relative terms, changes were stronger, with the strongest decrease when all cases were considered, irrespective of the treating department (0.08% per year; Table 2).

Hospital beds

Hospital beds in radiotherapy departments decreased on average by 51.5% (95% CI: 40.1–63%) per year, starting with 3111 beds in 2008 and falling to 2672 in 2017 (Fig. 5). There was little change in the number of days of hospitalization per bed (0.5 days per bed and year, 95% CI: 0.1–1.0) considering all cases in radiotherapy departments. However, in cases treated with radiochemotherapy, the days spent hospitalized increased by 0.64 days per bed (Fig. 5b).

Proportion of fractions under radiochemotherapy

When we plotted the proportion of fractions under radio- and chemotherapy during hospitalization, we found a steady increase starting from 40.1% in 2008 and climbing to 48.3% in 2017 (Fig. 6).

Sensitivity and additional analysis

The plot of the monthly average of the CCI in relation to department revealed a steady increase in comorbidities of considered cases. Comparing the CCI between departments, we found that the average CCI increased significantly more in radiotherapy than in non-radiotherapy departments (Fig. 7). When we performed the sensitivity analysis of OPS procedures between 8-521 and 8-525, we found little change in the computed estimates (Figs. 1, 2 and 3).

Discussion

Based on German inpatient data, we found that about half of all inpatient cases received their treatment (days of hospitalization and fractions) in genuine radiotherapy departments. In addition, we found a minor decrease in the proportion of cases with treatment in radiotherapy departments from 2008. A decrease in the number of hospital beds accompanied this trend. In addition, patients of all departments
Cases with radiochemotherapy rose only slightly throughout the observational period.

The trend of a slow decrease in total cases of radiotherapy departments, but at least constant numbers in cases receiving radiochemotherapy, might reflect a trend for outpatient treatment. Likewise, the total days of hospitalization decreased constantly throughout the observational period. However, we know little about the development of outpatient treatment in Germany as information are difficult to collect from claims data and are not part of the DRG statistics.

This development is in contrast to a constant number of incident cancer cases since 2008 when all entities are concerned [14]. In the three entities with the highest absolute consumption of radiotherapy according to Wong et al. [15] (breast cancer, prostate cancer, lung cancer), incident cases decreased (prostate, breast) or remained constant (lung in men), but rose in female lung cancer patients. Thus, the observed decreasing trend in case numbers and hospitalization

---

**Fig. 4** Days of hospitalization in radiotherapy departments differentiating between all radiotherapy and radiotherapy with simultaneous chemotherapy procedures, respectively. Absolute number (red), Smoothed temporal course (black) with 95% confidence intervals (green).
time fails to reflect the overall constant number of newly diagnosed cancer cases in Germany in the observational period.

Our data give evidence to the notion that radiotherapy remains a discipline with an important inpatient component. As treatment becomes more complex and patients become older, radiotherapy clinics could sustain steady case numbers. However, the total amount spent in radiotherapy departments decreased slightly over time, indicating a tendency to shorter hospital stays. These results need to be compared to the small magnitude of the effect. Likewise, as the number of fractions remained constant over time, a possible trend toward hypofractionation and acceleration, as propagated for prostate and breast cancer by recent studies [16, 17], is not present in our data. However, the treatment for both entities will for the most part take place in an outpatient clinic. Considering the inpatient setting, other concepts such as a simultaneous integrated boost instead or accelerated concepts [18], most prominently in the treatment of head and neck cancer [19, 20], might contribute to shorter hospitalizations.

Shorter times of hospitalization went with a decreasing number of hospital beds in radiotherapy departments in Germany. However, hospital beds declined to a similar extent as the total time of hospitalization. Thus, there is no indication of a shortage of treatment capacities in radiothera-
apy when early years are the reference. This might mitigate the threat of longer waiting times for hospitalization and the initiation of treatment with detrimental effects for the clinical outcome [21]. On the other hand, the number of beds seems to have adapted to a slightly decreasing demand. The fact that case numbers were stable during the entire observational period gives rise to the notion that per admission, cases tend to spend fewer days hospitalized [22]. However, the dip in case numbers between 2011 and 2012 might be due to differences in the DRG coding system when cases with IMRT and conventional external radiotherapy were coded as separate DRGs in 2011, but not in 2012, resulting in fewer recorded admissions in 2011 due to the merger of cases.

Where radiochemotherapy in radiotherapy departments is concerned, we found a minor increase in the number of admitted cases, which was accompanied by a decrease in the number of days spent hospitalized. However, the magnitude of the effect is comparable to the general decline in hospitalization time in all radiotherapy cases, irrespective of the department. Changing treatment patterns avoiding intravenous chemotherapy as in rectal cancer [23] or the establishment of weekly treatment regimens for the treatment of esophageal cancer [24] might contribute. However, such alterations are difficult to estimate as they depend strongly on the entity and particular protocols, as in the case of total neoadjuvant treatment for rectal cancer, where there are protocols with and without additional chemotherapy [25, 26].

Finally, even after the introduction of advanced technologies such as stereotactic radiotherapy, external beam radiotherapy remains the corner stone of inpatient treatment. Although case numbers decreased more pronouncedly in radiotherapy institutions, the average number of comorbidities increased. Thus, the overall workload of inpatient care might even have increased, with a considerable focus on more complex disorders. Thus, inpatient care in radiotherapy might become more specialized, while treatment of patients in better clinical conditions might move to outpatient care. As cases treated in radiotherapy departments had a higher CCI, which even increased over time, it becomes evident that there is a strong need for inpatient care in radiotherapy. In addition, the treatment landscape might be more selective when in- and outpatient treatment is considered, while a smaller proportion of cases in a worse clinical condition might form the future inpatient cohort. Radiotherapists need to adapt to this change in patient characteristics with, e.g., sufficient quality of multidisciplinary training in the treatment of complex patients.

Until 2011, distinct DRG codes were used for IMRT and conventional 3D radiotherapy in head and neck cancer. The merger of both DRGs in the catalogue might have led to different concepts of inpatient radiotherapy. However, this change in coding failed to affect the number of fractions or hospitalization time.

Related to this fact, the observed steady decrease in the total duration of hospitalization might be due to better ambulatory treatment, especially in the case of palliative care, and less toxic treatments allowing patients to move to an outpatient setting more easily. Outpatient palliative care was introduced in Germany in 2007, which is in line with the start of the observational period in our study.

The development of more specialized treatment facilities might have contributed to fewer cases treated in radiotherapy departments. Therapies such as complex palliative care (Palliative Komplexbehandlung), which is reimbursable since 2005 [27], might have shifted cases away from radiotherapy institutions. As a recent survey demon-
strated, there is a relevant need for palliative care in radiation oncology [27]. Especially the concept of early palliative care might motivate professionals to favor non-radiotherapy options more frequently [28].

Another contributing factor might be an increase in the number of multidisciplinary oncology departments, making a clear distinction of radiotherapy departments difficult.

In addition, regulatory measures might have an additional effect. However, limits of reimbursement changed sporadically over time [29] and were of small magnitude. Still, the overall effect size of changes in hospital days per case were small in magnitude (within the limits of 1 day per case). Nevertheless, this might not reveal the whole picture of monetary incentives to reduce hospitalization time.

**Limitations**

The most important limitation concerns the availability of inpatient data only. Thus, our findings fail to reveal the overall application of radiotherapy in Germany and the interpretation needs to consider this aspect. Thus, we cannot estimate the proportion of patients with treatment in a hospitalized setting. Although we found a decreasing proportion of cases treated in radiotherapy institutions alongside more complex cases, we fail to assess comorbidities and temporal trends of all patients treated by radiotherapy.

Furthermore, the dataset contains cases rather than actual patients. This limitation is especially relevant when rehospitalization in relation to absolute case numbers is concerned. Here, repetitive admissions of single patients might confound absolute case numbers. Thus, cases of one patient with short intervals between admissions might show up as a single case in the respective claims data. We tried to overcome this limitation by also considering total days of hospitalization, which are not subject to this limitation.

Changes in the DRG recording system might have an additional effect on computed estimates, which might explain the strong decrease in cases between 2011 and 2012. Cases treated in radiotherapy and non-radiotherapy departments play a minor role in our data, with no apparent change in case numbers. Still, this group might be subject to stronger changes in the near future, when multimodal treatment becomes more established. Furthermore, the data, by showing absolute numbers, report the effect from a provider’s perspective.

In an era of an aging population, the observed trend might even change in the near future, with a higher demand for inpatient radiotherapy [30]. This might lead to an insufficient supply of hospital beds in radiotherapy departments.

**Conclusion**

Overall, we observed a decrease in inpatient radiotherapy. Total cases and fractions spent in radiotherapy departments decreased constantly during the observation period. This was also true for total days hospitalized in radiotherapy departments and number of radiotherapy beds.

In conclusion, there is a tendency that inpatient treatment shifts from radiotherapy departments to other disciplines. This has wide-ranging consequences for medical training and education in radiation oncology and the quality of medical care. Even more, the decrease in case numbers might also extend to radiochemotherapy in future years. On the other hand, the increasing severity of cases in terms of comorbidities might reflect a general trend towards more selective and complex inpatient cases. If this is true, we might experience a stronger need for advanced inpatient care focused on patients in poor health along with a wide availability of outpatient institutions to treat patients in a sufficient health condition as appropriate. In either case, the inpatient part of radiotherapy might be subject to important changes to which the field of radiotherapy needs to adapt.

Finally, inpatient cases remain a cornerstone of radiotherapy in Germany. This needs to be added to the general workload for radiation oncologists in Germany [31].

**Supplementary Information** The online version of this article (https://doi.org/10.1007/s00066-021-01829-7) contains supplementary material, which is available to authorized users.

**Funding** Open Access funding enabled and organized by Projekt DEAL.

**Conflict of interest** D. Medenwald, R. Fietkau, G. Klautke, S. Langer, F. Würschmidt, and D. Vordermark declare that they have no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Ferlay J et al (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18(3):581–592
2. Hofmarcher T, Brådvik G, Svedman C, Lindgren P, Jönsson B, Wilking N (2019) Comparator report on cancer in Europe 2019—disease burden, costs and access to medicines. IHE, Lund
3. Rosenblatt E et al (2013) Radiotherapy capacity in European countries: an analysis of the Directory of Radiotherapy Centres (DIRAC) database. Lancet Oncol 14(2):e79–86
4. Barton MB, Zuzibarretta EH, Polo Rubio JA (2017) Radiotherapy in small countries. Cancer Epidemiol 50(Pt B):257–259
5. Bentzen SM et al (2005) Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol 75(3):355–365
6. Datta NR, Samiei M, Bodis S (2014) Radiotherapy infrastructure and human resources in Europe—present status and its implications for 2020. Eur J Cancer 50(15):2735–2743
7. Borras JM et al (2016) How many new cancer patients in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis. Radiother Oncol 119(1):5–11
8. Auperin A et al (2010) Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28(13):2181–2190
9. Bonner JA et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567–578
10. Tao Y et al (2018) Improved outcome by adding concurrent chemotherapy to cetuximab and radiotherapy for locally advanced head and neck carcinomas: results of the GORTEC 2007-01 phase III randomized trial. J Clin Oncol. https://doi.org/10.1200/JCO.2017.76.2518
11. Gillison ML et al (2019) Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 393(10166):40–50
12. Mehanna H et al (2019) Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet 393(10166):51–60
13. Forschungsdatenzentrum der Statistischen Ämter der Länder (2016) Diagnosis-related group statistics (DRG statistics). https://www.forschungsdatenzentrum.de/en/health/drg. Accessed 23 May 2016
14. Robert-Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland (2019) Krebs in Deutschland für 2015/2016. RKI, Berlin
15. Wong K, Delaney GP, Barton MB (2016) Evidence-based optimal number of radiotherapy fractions for cancer: a useful tool to estimate radiotherapy demand. Radiother Oncol 119(1):145–149
16. Jagsi R et al (2014) Adoption of hypofractionated radiation therapy for breast cancer after publication of randomized trials. Int J Radiat Oncol Biol Phys 90(5):1001–1009
17. Hocht S et al (2017) Hypofractionated radiotherapy for localized prostate cancer. Strahlenther Onkol 193(1):1–12
18. Dirkx ML, van Sörensen De Koste JR, Senan S (2004) A treatment planning study evaluating a ‘simultaneous integrated boost’ technique for accelerated radiotherapy of stage III non-small cell lung cancer. Cancer Treat Res 45(1):57–65
19. Franceschini D et al (2013) Simultaneous integrated boost-intensity-modulated radiotherapy in head and neck cancer. Laryngoscope 123(12):E97–E103
20. Lerbutsayanukul C et al (2018) A randomized phase III study between sequential versus simultaneous integrated boost intensity-modulated radiation therapy in nasopharyngeal carcinoma. Strahlenther Onkol 194(5):375–385
21. Barton MB et al (2014) Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012. Radiother Oncol 112(1):140–144
22. Pintova S et al (2015) Impact of inpatient radiation on length of stay and health care costs. J Community Support Oncol 13(11):399–404
23. Sauer R et al (2012) Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30(16):1926–1933
24. van Hagen P et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366(22):2074–2084
25. Conroy T et al (2021) Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22(5):702–715
26. Bahadoer RR et al (2021) Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 22(1):29–42
27. Fels J et al (2019) Palliative care in everyday practice of radiation oncologists. Strahlenther Onkol 195(7):659–667
28. Temel JS et al (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363(8):733–742
29. Institut für das Entgeltsystem im Krankenhaus (2021) Archiv. https://www.g-drg.de/Archiv. Accessed 25 June 2021
30. Kraywinkel K, van Oorschot B (2019) Veränderungen von Überlebensraten und Tumorcharakteristika mit zunehmendem Alter: Ergebnisse aus bevölkerungsbezogenen Krebsregistern. Onkologe 25(9):741–747
31. Budach W et al (2011) Evaluation of time, attendance of medical staff, and resources during radiotherapy for head and neck cancer patients: the DEGRO-QUIRO trial. Strahlenther Onkol 187(8):449–460